Objective: To explore the clinical effect of Magnesium Polarization Liquid and Meglumine Adenosine Cyclophosp hate in the treatment of intractable heart failure. Methods: 65 cases of intractable heart failure in our hospital were divided into treatment group (32 cases), control group (33 cases). All patients were given common treatment of heart failure,with control group treated by Magnesium Polarization Liquid and treatment group treated by Magnesium Polarization in cojunction to Meglumine Adenosine Cyclophosphate. The clinical effect of two groups were observed and compared.Results: The total effective rate of the treatment group was 90.6％, the control group was 69.7％, there was a significant difference between two groups (x2=4.45,P＜0.05). There were 22 cases with grade Ⅰ hearts function classification, 5 cases with grade Ⅱ hearts function classification, account for 84.4％. There was a significant difference between two groups of hearts function classification (Z=2.01 , P＜0.05). Both groups had no serious adverse reactions during treatment. Conclusion: There is obvious clinical effect and hearts function improvement of Magnesium Polarization Liquid and Meglumine Adenosine Cyclophosphate on treating intractable heart failure, which would be supplied in clinical practice.%目的:探讨极化镁液加环磷腺苷葡胺注射液治疗顽固性心力衰竭(心衰)的临床疗效.方法:将我院65例顽固性心衰患者随机分为治疗组32例、对照组33例.对照组给予常规抗心衰治疗并联合应用极化镁液辅助治疗,治疗组在对照组治疗基础上加用环磷腺苷葡胺注射液治疗.观察并比较两组疗效.结果:治疗组总有效率为90.6%,对照组总有效率为69.7%.两组总有效率比较,差异有统计学意义(χ2=4.45,P<0.05).治疗组治疗后心功能Ⅰ级22例,心功能Ⅱ级5例,共占84.4%,两组治疗后心功能分级分布比较,差异有统计学意义(Z=2.01,P<0.05).两组治疗期间均未见严重不良反应.结论:极化镁液与环磷酸腺苷葡胺联合治疗顽固性心衰临床治疗效果确切,患者心功能改善明显,值得进一步临床实践.
展开▼
